PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392087
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392087
Patient Derived Xenograft Model Market, By Model Type, By Implantation Method, By Tumor Type, By Application, By End User, By Geography
The Patient Derived Xenograft Model Market size is expected to reach US$ 346 million by 2030, from US$ 105.4 million in 2023, at a CAGR of 18.5% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 105.4 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 18.50% | 2030 Value Projection: | US$ 346 Mn |
Patient Derived Xenograft (PDX) Model is a cutting-edge preclinical research tool used in oncology research. It is a type of tumor model where tumor tissues from cancer patients are implanted into mice or other immunodeficient animals to create a more realistic representation of the tumor's behavior in humans. PDX models have gained significant popularity in drug discovery and development due to their ability to mimic patient-specific tumor characteristics and response to treatments.
This theoretical informative blog aims to provide an overview of the Patient Derived Xenograft Model market, including its market dynamics and key features. It will assist stakeholders in understanding the current and future trends in this market and making informed decisions.
Market Dynamics:
The Patient Derived Xenograft Model market is expected to witness substantial growth in the coming years. Several factors are driving this market expansion. Firstly, the increasing prevalence of cancer globally is creating a strong demand for effective treatment options. PDX models offer a valuable tool for studying tumor biology, evaluating drug efficacy, and identifying personalized treatment strategies.
Moreover, the rising focus on precision medicine and personalized therapies further contributes to the growth of the PDX model market. These models provide a platform for testing novel drug candidates and evaluating their potential response in specific patient cohorts. Additionally, the growing adoption of PDX models by pharmaceutical and biotechnology companies for preclinical testing is boosting market growth.
However, the Patient Derived Xenograft Model market also faces some challenges. One of the key restraints is the high cost associated with creating and maintaining PDX models. The complexity of these models, including genetic heterogeneity and the need for specialized infrastructure and expertise, adds to the overall expenses.
Nevertheless, the market presents several attractive opportunities for key players. Advancements in technology, such as genome editing tools and humanized mouse models, enhance the utility and translatability of PDX models. Moreover, collaborations between pharmaceutical companies, academic research institutions, and contract research organizations are likely to further accelerate the adoption and availability of PDX models.
Key Features of the Study:
This study on the Patient Derived Xenograft Model market encompasses various essential features, providing comprehensive insights into the market landscape:
- Market Size and Growth: The report offers an in-depth analysis of the global Patient Derived Xenograft Model market, including market size (in US$ Million) and compound annual growth rate (CAGR%) for the forecast period of 2023-2030, with 2022 as the base year.
- Revenue Opportunities: It elucidates potential revenue opportunities across different market segments and presents attractive investment proposition matrices, aiding stakeholders in identifying lucrative opportunities.
- Market Drivers, Restraints, and Opportunities: The study provides key insights into market drivers, restraints, and opportunities, shedding light on factors influencing market growth. It also highlights new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- Company Profiles: Key players in the global Patient Derived Xenograft Model market are profiled based on parameters such as company highlights, product portfolio, key achievements, financial performance, and strategies. The list of companies covered in this study includes THE JACKSON LABORATORY, Champions Oncology, Inc, Charles River Laboratories, Crown Bioscience, Hera Biolabs, Horizon Discovery Ltd., Oncodesign, Pharmatest Services, Shanghai LIDE Biotech, Aragen Life Sciences Ltd., Creative Animodel, Urosphere, Applied StemCell and WuXi AppTec.
- Decision-Making Insights: The report equips marketers and management authorities with valuable insights to make informed decisions regarding product launches, type up-gradation, market expansion, and marketing tactics.
- Stakeholder Benefits: The global Patient Derived Xenograft Model market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts. It provides ease in decision-making through various strategy matrices utilized in analyzing the market.
Patient Derived Xenograft Model Market Segmentation:
- By Model Type
- Tumor explant models
- Cell line derived models
- Patient derived organoids
- Genetically engineered models
- Others (Primary cell derived models, cell processed models etc.)
- By Implantation Method
- Subcutaneous Implantation
- Orthopedic Implantation
- Others
- By Tumor Type
- Gastrointestinal Tumor Model
- Gynecological Tumor Model
- Respiratory Tumor Model
- Other Tumor Model
- By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutions
- Others
- By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Top companies in Patient Derived Xenograft Model Market:
- THE JACKSON LABORATORY
- Champions Oncology, Inc
- Charles River Laboratories
- Crown Bioscience
- Hera Biolabs
- Horizon Discovery Ltd.
- Oncodesign
- Pharmatest Services
- Shanghai LIDE Biotech
- Aragen Life Sciences Ltd.
- Creative Animodel
- Urosphere
- Applied StemCell
- WuXi AppTec
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Patient Derived Xenograft Model, By Model Type
- Market Patient Derived Xenograft Model, By Implantation Method
- Market Patient Derived Xenograft Model, By Tumor Type
- Market Patient Derived Xenograft Model, By End User
- Market Patient Derived Xenograft Model, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Increasing Cancer Research
- Restraints
- Limitations of PDX Models
- Opportunities
- Applications in Immunotherapy Testing
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Patient Derived Xenograft Model Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Patient Derived Xenograft Model Market , By Model Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Tumor explant models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Cell line derived models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Patient derived organoids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Genetically engineered models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Others (Primary cell derived models, cell processed models etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
6. Patient Derived Xenograft Model Market , By Model Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Subcutaneous Implantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Orthopedic Implantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
7. Patient Derived Xenograft Model Market , By Tumor Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018- 2030
- Gastrointestinal Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
- Gynecological Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
- Respiratory Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
- Other Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
8. Patient Derived Xenograft Model Market , By End User, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018- 2030
- Segment Trends
- Pharmaceutical & Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
- Contract Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
- Academic & Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
9. Patient Derived Xenograft Model Market , By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- THE JACKSON LABORATORY
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Champions Oncology, Inc
- Charles River Laboratories
- Crown Bioscience
- Hera Biolabs
- Horizon Discovery Group
- Oncodesign
- Pharmatest Services
- Shanghai LIDE Biotech
- Aragen Life Sciences Ltd.
- Creative Animodel
- Urosphere
- Applied StemCell
- WuXi AppTec
- Analyst Views
11. Section
- Research Methodology
- About us
